Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress
Huageng Huang, Le Yu, Huawei Weng, Wei Zhang, Zhao Wang, Lin Wang, He Huang · 2024
Read Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress by Huageng Huang, Le Yu, Huawei Weng, Wei Zhang, Zhao Wang, Lin Wang, He Huang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11622581.txt.
Description
Huang and six co-authors wrote a review in twenty twenty-four on CAR-T cell therapy updates from a major cancer congress. The therapy retools a patient's T cells to hunt cancer. Blood cancers respond strongly; solid tumors show early promise. Weak cell growth, side effects, and scarce targets still limit reach. Tumor surroundings also block cell entry and sap strength. Congress reports tackle those walls from many angles. Cytokine tuning and new targets headline the strategies.
Donor-made cells, vaccine pairings, and in-body delivery appear too. Switchable activation aims to tame side effects. The review gathers the year's field directions in one place. It suits readers tracking cell therapy's frontier.
Catalog record
| CREATOR | Huageng Huang, Le Yu, Huawei Weng, Wei Zhang, Zhao Wang, Lin Wang, He Huang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |